secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2024-05-20T23:59:59+00:00
Accession:  0001493152-24-020707
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma receives FDA approval for generic Methotrexate; market $64.3M annual sales
--------------------------------------------------------------------------------

- FDA approved ANDA for generic Methotrexate Sodium 2.5 mg tablets on May 16, 2024.
- Product will be marketed under Elite Laboratories, Inc. label.
- IQVIA reports $64.3 million in annual U.S. generic market sales (12 months ending Mar 2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224020707/0001493152-24-020707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224020707/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer